Thus, the antibodies blocking CTLA-4 and PD-1 and its ligand PD-L1 show promising anti-tumor effects in a wide range of tumor types by priming T cells against tumor antigens [122,123,124,125]. The gene discussed is CTLA4; the disease is neoplasm.